×
0 0 0 0 0 0 -0.0289962825278811 -0.0468401486988848
Stockreport

Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mu...

BLUEPRINT MEDICINES CORP COMMON (BPMC)  More Company Research Source: PR Newswire
Last blueprint medicines corp common earnings: 5/2 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
PDF CAMBRIDGE, Mass., June 5, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1 clinical data and outlined registration plans for BLU-285, a potent and highly selective PDGFRa and KIT inhibitor in development as a potential treatment for patients with advanced gastrointestinal stromal tumors (GIST). In patients with PDGFRa-driven GIST harboring a D842 mutation, the data showed an objective response rate (ORR) of 60 percent and an estimated 9-month progression free survival (PFS) of 87 percent. Among patients with treatment-resistant KIT-driven GIST, tumor reduction was observed in eight of 14 evaluable patients treated at dose levels of at least 300 mg once daily (QD). BLU-285 was well tolerated, and most adverse events (AEs) reported by investigators were Grade 1 or 2. The data will be presented today in an oral presentation durin [Read more]

IMPACT SNAPSHOT EVENT TIME: BPMC
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS